Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / VCAN



This biomarker is also known as:
  • Large fibroblast proteoglycan,
  • Glial hyaluronate-binding protein,
  • WGN,
  • WGN1,
  • CSPG2,
  • Chondroitin sulfate proteoglycan core protein 2,
  • ERVR,
  • versican,
  • versican proteoglycan,
  • versican core protein,
  • GHAP,
  • PG-M,
  • chondroitin sulfate proteoglycan 2,

View in BioMuta


VCAN, or CSPG2, a large chondroitin sulfate proteoglycan, is a major component of the extracellular matrix. This secreted protein is involved in cell adhesion, proliferation, migration and angiogenesis and plays a central role in tissue morphogenesis and maintenance. It is may play a role in intercellular signaling. Mutations in the CSPG2 gene are the cause of Wagner syndrome type 1. Multiple transcript variants encoding different isoforms have been found for this gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Under Review


VCAN (CSPG2) was shown to localize to vascular-like structures in ovarian cancer but not in normal ovaries.

Performance Comment

VCAN, or CSPG2, was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of VCAN was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.